Company profile for Poplar Therapeutics

NEW Drugs in Dev: 1
PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Poplar Therapeutics is a clinical-stage immunology company revolutionizing atopic disease treatment with a next-generation anti-IgE therapy. Launched in 2026 with $50M Series A funding (led by SR One and Vida Ventures), its lead candidate PHB-050 features a unique triple-action mechanism to rapidly deplete IgE levels, targeting food allergy, asthma, and atopic dermatitis. Backed by experienced leadership from 2seventy bio and ...
Poplar Therapeutics is a clinical-stage immunology company revolutionizing atopic disease treatment with a next-generation anti-IgE therapy. Launched in 2026 with $50M Series A funding (led by SR One and Vida Ventures), its lead candidate PHB-050 features a unique triple-action mechanism to rapidly deplete IgE levels, targeting food allergy, asthma, and atopic dermatitis. Backed by experienced leadership from 2seventy bio and others, Poplar aims to enable effective therapies for high-IgE patients underserved by current options like Xolair®.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Cambridge, Massachusetts
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty